Brooks Laboratories has received an approval for manufacture of Doripenem Monohydrate injection from Directorate General of Health Service. The company is all set to manufacture this drug within this fiscal year.
Doripenem is a broad spectrum anti-bacterial agent of carbapenem family. Growing bacterial resistance is major cause of concern for researchers as it contributors to increase in mortality, morbidity and treatment cost. Doripenem is an ultra broad spectrum anti bacterial agent of carbepenem family used to treat in complicated intra-abdominal infections and complicated urinary tract infections, including complicated and uncomplicated pylenephritis and cases with concurrent bacteremia.
Brooks Laboratories is into pharmaceutical contract research and manufacturing services. It is having wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1935.25 |
| Dr. Reddys Labs. | 1245.50 |
| Cipla | 1438.75 |
| Zydus Lifesciences | 1150.50 |
| Lupin | 2496.05 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: